Established in 2020, PlexusDx is a high-complexity CLIA certified and COLA accredited laboratory specializing in Pharmacogenomics (PGx). We built a turnkey platform that empowers healthcare/wellness providers to offer precision medication decision support, population health, and comprehensive medication therapy management. Helping pharmacists, clinics, and counselors do well by doing good.

CANCER FUND is dedicated to investing in early-stage companies that are making strides in therapies and management, diagnostics and monitoring, and preventions and enabling technologies. Their investments aim to benefit a wide range of stakeholders, including patients and families, medical professionals and caregivers, at-risk populations, as well as payers and policymakers. By focusing on the crucial gap that falls between the stages of research grants and the interest of most venture capitalists, CANCER FUND specializes in Pre-Seed, Seed, Seed+, and Series A funding rounds, targeting innovations that promise to make significant impacts in the fight against cancer.

-Spearheaded and efficiently managed mergers and acquisitions, notably the acquisition and seamless integration of a CLIA licensed infectious disease laboratory, significantly enhancing the company's service capabilities and market reach.- Scaled the company's revenue from zero to $XXM within a span of 18 months- Raised Seed and Series A equity/debt financing